Awans, Belgium, 17 February 2022 – CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatmentof coronary artery disease that causes heart attacks, announces today that it has received additional funding of € 12.3 million. The proceeds will be used to launch a new clinical study and support the development of the next generation cryotherapy system for commercial launch. Moreover, the funding will allow the Company to further tap into the rich local ecosystem of talent in the Walloon region as it continues to build its team and collaborations with local partners as it develops its technology.
Click here to read the press release
